Meiji Yasuda Asset Management Co Ltd. Has $968,000 Holdings in DaVita Inc. (NYSE:DVA)

Meiji Yasuda Asset Management Co Ltd. lessened its position in shares of DaVita Inc. (NYSE:DVA) by 57.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,472 shares of the company’s stock after selling 8,890 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in DaVita were worth $968,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DVA. JPMorgan Chase & Co. raised its stake in shares of DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares during the last quarter. Amundi raised its position in shares of DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after acquiring an additional 240,126 shares during the last quarter. KBC Group NV lifted its stake in shares of DaVita by 0.8% in the 4th quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after purchasing an additional 2,636 shares during the period. BNP Paribas Financial Markets boosted its position in shares of DaVita by 23.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock worth $47,874,000 after purchasing an additional 56,389 shares during the last quarter. Finally, Nordea Investment Management AB increased its holdings in DaVita by 4.9% in the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after purchasing an additional 12,339 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

Shares of NYSE DVA opened at $151.30 on Thursday. The company has a fifty day moving average price of $157.96 and a 200 day moving average price of $157.53. The firm has a market cap of $12.10 billion, a PE ratio of 14.09, a PEG ratio of 1.07 and a beta of 0.99. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Barclays boosted their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. StockNews.com lowered shares of DaVita from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.